CloneID: D2E7 (Adalimumab)
Heavy Chain modification: His-Tagged
Antigen Long Description: This antibody was generated by affinity maturation from the 2SD4 scFv, which in turn was selected on human TNF alpha by guided phage-display technology, using the murine anti-hTNF alpha antibody Mab32 as a template (c.f. also US Patent 6090382).
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P01375
Specificity Statement: Binds to soluble TNF-alpha, but not to lymphotoxin (TNF beta).
Application Notes (Clone): Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab, unlike Infliximab (Ab00146), was shown to be cross-reactive with mouse TNF alpha (Arnoult 2017, PMID: 28584008).
English
Deutsch
